Month: March 2026

HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology, infrastructure, and services company, today announced its financial results for the fourth quarter and full-year ended December 31, 2025. Intuitive Machines CEO Steve Altemus said, “2025 was a transformational year for Intuitive Machines. We completed our second lunar mission, expanded into national security space programs, closed the acquisition of KinetX Aerospace, and announced the acquisition of Lanteris Space Systems. These acquisitions significantly expand our scale, addressable market, and growth opportunities.” HighlightsCompleted $800 million acquisition of Lanteris Space Systems in Q1 2026 to be a vertically integrated next-generation space prime contractor for commercial,...

Delivered record-high revenues, Adjusted EBITDA1, Adjusted EBITDA per share1 since inceptionGenerated record high cash flow from operations since inceptionProvides 2026 revenues guidance of $490 million to $510 million and adjusted EBITDA1 of approximately 15% MONTREAL, March 19, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2025 Highlights Financial resultsRevenues were $450,088, an increase of $78,784 or 21% over the prior year. The increase was primarily driven by the incremental revenues from...

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS) InflaRx actively reviewing and considering additional development in ANCA‑associated vasculitis (AAV) To broaden izicopan signal-finding activities and expedite proof-of-concept studies into additional indications in inflammation and immunology (I&I), InflaRx intends to conduct a pharmacokinetic (PK) bridging study in China this year Active dialog with potential collaborators to expedite the Company’s total pipeline development goals continues InflaRx to host a virtual Capital Markets Day this spring to detail the expected clinical development path for izicopan in HS and to highlight its...

Completed a strategic growth investment in the fourth quarter into Ability Insurance Company, significantly improving capital ratios and enabling expansion of its business  Mount Logan-managed fund signed a definitive agreement during first quarter 2026 to acquire $100+ million of assets from Yieldstreet Alternative Income Fund, which is expected to increase annual FRE1 by at least $2.8 million2 Entered an agreement during the first quarter 2026 to manage $125 million of additional assets, which is expected to increase FRE by approximately $0.5 million in 2026 and in excess of $1.0 million in 2027  Declared quarterly distribution of $0.03 per common share in the first quarter of 2026, the second shareholder distribution for Mount Logan as a US registrant Mount Logan to host a conference call on Thursday, March 19, 2026, at 12:00 PM Eastern...

Recurring Revenue at 81% of Total Revenue Q4 2025 HighlightsRevenue (in $ millions)SaaS Subscription Recurring TotalReported Y/Y growth Reported Y/Y growth Reported Y/Y growth$8.6 12.4% $11.7 6.5% $14.4 (6.2)%SaaS ARR up 9% Y/Y to $ 33.8 million; Total ARR up 2% Y/Y to $ 45.7 million; SaaS ARR Bookings up 8.1% Y/Y to $0.5 million; Gross Profit margin of 56%; Recurring Revenue at 81% of Total Revenue; Adjusted EBITDA1 margin of 7.2% or $1.0 million; and Net Loss of $0.9 millionFiscal 2025 Highlights  Revenue (in $ millions)  SaaS Subscription Recurring TotalReported Y/Y growth Reported Y/Y growth Reported Y/Y growth$32.5 10.6% $45.0 3.8% $62.2 (5.1)%SaaS NRR of 101%; SaaS ARR Bookings up 2% Y/Y to $4.3 million; Gross Profit margin of 58%; Recurring Revenue at 72% of Total Revenue; Project Services Revenue...

Titan is positioning itself to establish the first domestic end-to-end natural graphite supply chain in the U.S. in over seventy years GOUVERNEUR, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Titan Mining Corporation (NYSE-A:TII, TSX:TI), (“Titan” or the “Company”) an established zinc concentrate producer in upstate New York and the only end-to-end producer of natural flake graphite in the U.S., today announced solid financial and operational results for the fourth quarter and full year ended December 31, 2025. Q4 AND FY 2025 HIGHLIGHTS(1)(2)(3) Operating and Financial Performance:Zinc production: 18.7 million payable pounds in Q4 2025 and 64.3 million payable pounds for the full year, up 8% from FY 2024, representing record production at Empire State Mines (“ESM”) and achieving 2025 production guidance Revenues: $25.1 million in Q4...

Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meeting Topline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved                                                                                                           Successful closing of $115 million February 2026 public offering, that...

Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year period Fourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year period Adjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year period Maintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billionMaintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 millionAnnounced agreement to acquire Family First Homecare subsequent to the Fourth QuarterATLANTA, March 19, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period and fiscal year ended January 3, 2026. Jeff...